Journal
CANCER BIOMARKERS
Volume 31, Issue 4, Pages 329-338Publisher
IOS PRESS
DOI: 10.3233/CBM-203142
Keywords
Gastric cancer; peritoneal metastasis; ascites; paclitaxel-resistance; autoantibody
Categories
Funding
- National Natural Science Foundation of China [81772518]
- Multicenter Clinical Trial of Shanghai Jiao Tong University School of Medicine [DLY201602]
Ask authors/readers for more resources
This study identified novel autoantibodies in the ascites of relapsed PTX-resistant gastric cancer patients, including TPM3, EFHD2, KRT19, and vimentin. These autoantibodies may serve as potential biomarkers for monitoring the occurrence of PTX-resistance.
BACKGROUND: Gastric cancer (GC) patients with peritoneal metastasis usually have extremely poor prognosis. Intraperitoneal infusion of paclitaxel (PTX) provides an effective treatment, but relapse and PTX-resistance are unavoidable disadvantages, and it is difficult to monitor the occurrence of PTX-resistance. OBJECTIVE: The aim of this study was to explore novel autoantibodies in the ascites of individuals with relapsed PTX-resistant GC with peritoneal metastasis. METHODS: Ascites samples were collected before PTX infusion and after the relapse in 3 GC patients. To determine the expression of significantly changed proteins, we performed autoantibody profiling with immunome protein microarrays and tandem mass tag (TMT) quantitative proteomics, and then, the overlapping proteins were selected. RESULTS: Thirty-eight autoantibodies that were differentially expressed between the ascites in the untreated group and relapsed PTX-resistant group were identified. For confirmation of the results, TMT quantitative proteomics was performed, and 842 dysregulated proteins were identified. Four proteins, TPM3, EFHD2, KRT19 and vimentin, overlapped between these two assays. CONCLUSIONS: Our results first revealed that TPM3, EFHD2, KRT19 and vimentin were novel autoantibodies in the ascites of relapsed PTX-resistant GC patients. These autoantibodies may be used as potential biomarkers to monitor the occurrence of PTX-resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available